Bioanalytical Overview Parameters Substrate History · Evolution Current 2026 Future 2026-2035 AI lens Flow of trials Players & stakeholders Signals
Library/Bioanalytical Trials/Substrate
chapter 02 · the operational layer

Analytical substrate: platforms, regimes, lifecycle, matrices.

The operational architecture beneath every method. Five analytical platforms · regulatory regimes · the four-phase method lifecycle · matrix types. The substrate iFeed is built on.

/ 01

Analytical platforms.

5 instrument families

The analytical platform determines what's quantifiable, at what sensitivity, in what matrix. Choice of platform determines validation approach. Choice of platform determines regulatory expectations. The five families that cover the field today:

/ Platform 01

LC-MS/MS · triple quadrupole.

Workhorse for small molecules and peptides. SCIEX 5500/6500. Agilent 6470/6495. The default for PK/BE bioanalysis since the early 2000s.

/ Platform 02

HRAM · Orbitrap · Q-TOF.

High-resolution accurate-mass for biomarkers, peptides, identification work. Where LC-MS/MS leaves off and discovery-grade analysis begins.

/ Platform 03

HPLC-UV · PDA.

Older technology, limited sensitivity. Legacy methods that haven't migrated yet. Still seen in defined-impurity work and certain manufacturing contexts.

/ Platform 04

LBA · ligand-binding assays.

ELISA, MSD, immunoassays. Large molecules, biomarkers, biologics. The biopharma analytical staple where LC-MS struggles with sensitivity.

/ Platform 05

Hybrid LC-MS + IA.

Immunoaffinity capture + MS detection. The best-of-both for selected molecules — antibody-drug conjugates, low-abundance biomarkers.

/ 02

Regulatory regimes.

BA-specific guidance

ICH M10 is the central harmonised source for bioanalytical method validation and study-sample analysis. Each jurisdiction retains its own implementation pathway, legacy texts, and review habits, so iFeed treats this as a source family rather than a single one-size-fits-all checklist.

ICH M10
Bioanalytical method validation and study sample analysis. The central harmonised source text for current cross-region BMV interpretation.
2022
FDA BMV
FDA Bioanalytical Method Validation guidance. US-specific source anchor that remains useful alongside FDA's ICH M10 guidance page.
2018
EMA GLBIV
EMA Guideline on Bioanalytical Method Validation. Historical EU predecessor; EMA now hosts ICH M10 as the scientific guideline source.
2012
WHO PQ
WHO Prequalification programme bioanalytical guidance. Relevant for prequalification contexts; current source mapping should be checked against WHO/PQT guidance before making jurisdiction-specific claims.
source check
ANVISA
ANVISA bioanalytical source family. Brazilian expectations should be mapped from the current ANVISA text before public checklist claims are made.
source check
MHLW PMDA
MHLW/PMDA bioanalytical source family. Japanese implementation and review expectations need direct source anchoring before detailed operational claims.
source check
/ 03

Method lifecycle.

Development → retirement

The lifecycle is what reviewers and inspectors reconstruct. Each stage produces documentation; each stage feeds the next; each stage can create questions if the record is incomplete, inconsistent, or difficult to retrieve.

/ 01
Development.

Method scoping, fit-for-purpose criteria, prototype runs. Selectivity, sensitivity, range exploration.

/ 02
Validation.

Full validation per ICH M10 dimensions. Selectivity · accuracy · precision · linearity · stability · matrix effect.

/ 03
Sample analysis.

Production runs. Incurred sample reanalysis. Calibration curve, QC performance per run. Real-time review.

/ 04
Cross-validation.

Method-to-method, lab-to-lab, instrument-to-instrument when transfers occur. Bridging study design.

/ 05
Retirement.

Method retirement protocol. Long-term stability close-out. Archive, traceability, succession to revised method.

Source anchors: ICH M10 Step 4 guideline · FDA ICH M10 guidance page · EMA ICH M10 scientific guideline.

/ 04

Matrix types.

Where the analyte lives

The biological matrix dictates the validation approach. Plasma is the default; the others come with their own selectivity and stability questions, their own sample-collection complexity, their own regulator expectations.

/ Matrix 01
Plasma.

K2-EDTA, lithium heparin. The default bioanalytical matrix. PK studies, BE studies, biomarker quantitation.

/ Matrix 02
Whole blood.

Total drug exposure. Drugs that partition into red cells. Specific stability and haemolysis considerations.

/ Matrix 03
Serum.

Clot-derived. Used for biomarkers, immunogenicity, certain biologics. Different matrix-effect profile from plasma.

/ Matrix 04
Urine.

Excretion studies, mass balance, certain BE designs. pH and creatinine considerations.

/ Matrix 05
Tissue.

Skin, brain, liver biopsy. Distribution studies. Homogenisation, recovery, normalisation.

/ Matrix 06
CSF.

Cerebrospinal fluid. CNS drug distribution. Low-volume, high-stakes; compatibility with sensitive platforms.

/ Matrix 07
Dried blood spot.

DBS — finger-prick collection. Pediatric, low-resource, decentralised trials. Specific haematocrit and recovery validation.

/ Matrix 08
Saliva · other.

Therapeutic drug monitoring contexts. Free-fraction estimation. Specific to drug class and study purpose.

/ S

Source register.

official anchors · interpretation kept separate

This bioanalytical page uses official guidance as the source layer and separates iFeed interpretation from regulator text. Jurisdiction-specific details should be checked against the current regulator page before use in submissions, audits, or public checklists.

ICH

M10 Step 4.

Bioanalytical Method Validation and Study Sample Analysis guideline.

FDA

M10 and 2018 BMV anchors.

FDA M10 page · FDA 2018 BMV guidance.

EMA

ICH M10 EU page.

EMA ICH M10 scientific guideline. Earlier EMA BMV guidance should be marked as historical where used for comparison.